Autism Spectrum Disorders Clinical Trial
Verified date | October 2016 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of this study is to predict and explain on the basis of brain function and structure the behavioral and brain effects of an evidence-based intervention for adults with high-functioning autism, Virtual Reality-Social Cognition Training (Kandalaft et al., 2012; Journal of Autism and Developmental Disorders). Adults with autism will be randomly assigned to receive either (a) two hours per week of intervention services for five weeks, or (b) a treatment as usual control. The intervention will focus on enhancing social skills, social cognition, and social functioning. Outcome measures will evaluate changes in these social skills, cognition, and functioning using standardized assessments. We will perform structural and functional magnetic resonance imaging (MRI) scans at three time points-before, during, and after treatment (i.e., Time Point #1, 2, and 3).
Status | Completed |
Enrollment | 10 |
Est. completion date | June 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria: 1. Adults: 1. Age: 18-40, inclusive 2. A male or female outpatient 2. High-functioning (so that the treatment can effectively benefit the subjects): 1. Full Scale Intelligence Quotient (IQ) of WASI at least 80 2. Able to give informed consent prior to initiation of any protocol required procedures 3. Autism Spectrum Disorder: 1. Having a current primary diagnosis of Autism Spectrum Disorder (including Asperger's Disorder) from a licensed psychologist/psychiatrist or from a school diagnostician, as defined by the DSM-IV criteria. 2. For this project, diagnosis will not be determined by our assessment. The participants we enroll will already carry a current primary diagnosis of Autism Spectrum Disorder. This verification of their diagnosis may also come from study personnel who have seen and/or treated the patient prior to his or her involvement in the project and can verbally confirm that they carry the proper diagnosis. 4. Mean Length of Utterance (MLU) must be at least 4-5 words (the intervention method requires this) Exclusion Criteria: 1. Speech-language criteria: 1. Those who are not fluent in written and oral English will not be eligible to participate, as many of the instruments are not validated in other languages. 2. Significant hearing loss or other severe sensory impairment 3. Inability to read self-report instruments 2. Health criteria: 1. Those whose clinical status (e.g., serious suicidal or homicidal risk) requires inpatient or day hospital treatment 2. Those with a history of seizures, or current use of anticonvulsants 3. A fragile health status 4. A history of significant head trauma or serious brain or psychiatric illness 5. Having any other current psychiatric condition or complications, such as i. Diagnosed with substance dependence within the last three months. ii. Current use of prescription medications that may affect cognitive processes under study. iii. Current primary diagnosis of bipolar disorder I or II iv. Axis I psychopathology v. Depression 3. Any metal or electromagnetic implants, including: 1. Cardiac pacemaker 2. Defibrillator 3. Artificial heart valve 4. Aneurysm clip 5. Cochlear implants 6. Shrapnel 7. Neurostimulators 8. History of metal fragments in eyes or skin |
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Yale University | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University | University of Texas |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | functional magnetic resonance imaging (MRI) | up to 6 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02625116 -
ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders
|
||
Not yet recruiting |
NCT06381856 -
Improving Participation of Autistic Children and Adolescents in the Habilitation Process
|
||
Recruiting |
NCT02280746 -
Gluten for Autism Spectrum Disorders
|
N/A | |
Completed |
NCT01945957 -
Brain Imaging of Intranasal Oxytocin Treatment in Autism
|
Phase 1 | |
Completed |
NCT01661855 -
A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD
|
Phase 2 | |
Completed |
NCT01694667 -
Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder
|
Phase 2 | |
Completed |
NCT01780090 -
Handheld Technology for Speech Development in Students With Autism
|
N/A | |
Completed |
NCT01691066 -
Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder
|
N/A | |
Completed |
NCT01592747 -
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
|
Phase 2 | |
Active, not recruiting |
NCT01417026 -
Intranasal Oxytocin and Learning in Autism
|
Phase 2 | |
Enrolling by invitation |
NCT01364818 -
Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment
|
N/A | |
Completed |
NCT01695200 -
Omega-3 Fatty Acids in Autism Spectrum Disorders
|
Phase 4 | |
Completed |
NCT02300597 -
Internet-based Support for Young People With ADHD and Autism - a Controlled Study
|
N/A | |
Completed |
NCT01675414 -
Understanding Gastrointestinal Conditions in Children With Autism Spectrum Disorder (ASD)
|
N/A | |
Not yet recruiting |
NCT00695812 -
The Development of Younger Siblings of Children With Autism Now at 10 Years of Age
|
N/A | |
Recruiting |
NCT05910502 -
Project AFECT (Autism Family Empowerment Coaching and Training Program)
|
N/A | |
Completed |
NCT02081027 -
Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
|
Early Phase 1 | |
Completed |
NCT02797379 -
The Development of a Psychoeducational Tool to Manage Anxiety in People With Autism Spectrum Disorders
|
N/A | |
Terminated |
NCT01730079 -
Near Infrared Spectroscopy in Children With Autism and ADHD
|
||
Completed |
NCT01603225 -
Transcranial Direct Current Stimulation and Autism
|